References
- Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:20–33.
- French SL, Arthur JF, Tran HA, Hamilton JR. Approval of the first protease-activated receptor antagonist: rationale, development, significance, and considerations of a novel anti-platelet agent. Blood Rev 2015;29:179–189. doi:https://doi.org/10.1016/j.blre.2014.10.006.
- Wilson SJ, Ismat FA, Wang Z, Cerra M, Narayan H, Raftis J, Gray TJ, Connell S, Garonzik S, Ma X, et al. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. Arterioscler Thromb Vasc Biol 2018;38:448–456. doi:https://doi.org/10.1161/ATVBAHA.117.310104.
- French SL, Thalmann C, Bray PF, Macdonald LE, Murphy AJ, Sleeman MW, Hamilton JR. A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant. Blood Adv 2018;2:1283–1293. doi:https://doi.org/10.1182/bloodadvances.2017015552.
- Wong PC, Seiffert D, Bird JE, Watson CA, Bostwick JS, Giancarli M, Allegretto N, Hua J, Harden D, Guay J, et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med 2017:9(371). doi:https://doi.org/10.1126/scitranslmed.aaf5294.9(371):eaaf5294.
- Edelstein LC, Simon LM, Lindsay CR, Kong X, Teruel-Montoya R, Tourdot BE, Chen ES, Ma L, Coughlin S, Nieman M, et al. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood 2014;124:3450–3458. doi:https://doi.org/10.1182/blood-2014-04-572479.
- Edelstein LC, Simon LM, Montoya RT, Holinstat M, Chen ES, Bergeron A, Kong X, Nagalla S, Mohandas N, Cohen DE, et al. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med 2013;19:1609–1616. doi:https://doi.org/10.1038/nm.3385.
- Whitley MJ, Henke DM, Ghazi A, Nieman M, Stoller M, Simon LM, Chen E, Vesci J, Holinstat M, McKenzie SE, et al. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y12 inhibition. J Thromb Haemost 2018;16:2501–2514. doi:https://doi.org/10.1111/jth.14318.
- Tourdot BE, Stoveken H, Trumbo D, Yeung J, Kanthi Y, Edelstein LC, Bray PF, Tall GG, Holinstat M. Genetic variant in human par (protease-activated receptor) 4 enhances thrombus formation resulting in resistance to antiplatelet therapeutics. Arterioscler Thromb Vasc Biol 2018;38:1632–1643. doi:https://doi.org/10.1161/ATVBAHA.118.311112.
- French SL, Arthur JF, Lee H, Nesbitt WS, Andrews RK, Gardiner EE, Hamilton JR. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood. J Thromb Haemost 2016;14:1642–1654. doi:https://doi.org/10.1111/jth.13293.
- Ramstrom S, Oberg KV, Akerstrom F, Enstrom C, Lindahl TL. Platelet PAR1 receptor density–correlation to platelet activation response and changes in exposure after platelet activation. Thromb Res 2008;121:681–688. doi:https://doi.org/10.1016/j.thromres.2007.06.010.
- El-Tayeb A, Griessmeier KJ, Muller CE. Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors. Bioorg Med Chem Lett 2005;15:5450–5452. doi:https://doi.org/10.1016/j.bmcl.2005.08.104.
- Coller BS, Peerschke EI, Scudder LE, Sullivan CA. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 1983;61:99–110. doi:https://doi.org/10.1182/blood.V61.1.99.99.
- Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996;88:907–914. doi:https://doi.org/10.1182/blood.V88.3.907.907.
- Burkhart JM, Vaudel M, Gambaryan S, Radau S, Walter U, Martens L, Geiger J, Sickmann A, Zahedi RP. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012;120:e73–82. doi:https://doi.org/10.1182/blood-2012-04-416594.
- Zeiler M, Moser M, Mann M. Copy number analysis of the murine platelet proteome spanning the complete abundance range. Mol Cell Proteomics 2014;13:3435–3445. doi:https://doi.org/10.1074/mcp.M114.038513.
- Levi M, Keller TT, van Gorp E, Ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 2003;60:26–39. doi:https://doi.org/10.1016/S0008-6363(02)00857-X.
- Wallen NH, Goodall AH, Li N, Hjemdahl P. Activation of haemostasis by exercise, mental stress and adrenaline: effects on platelet sensitivity to thrombin and thrombin generation. Clin Sci (Lond) 1999;97:27–35. doi:https://doi.org/10.1042/cs0970027.